Cronos Group Inc.
$2.76
▲
0.8%
2026-04-21 06:14:01
thecronosgroup.com
NGM: CRON
Explore Cronos Group Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.4 B
Current Price
$2.76
52W High / Low
$4.66 / $2.35
Stock P/E
—
Book Value
$2.87
Dividend Yield
—
ROCE
-1.7%
ROE
-0.26%
Face Value
—
EPS
$-0.02
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
610
Beta
1.21
Debt / Equity
0.13
Current Ratio
19.59
Quick Ratio
18.62
Forward P/E
-64.5
Price / Sales
6.77
Enterprise Value
$196.73 M
EV / EBITDA
-58.67
EV / Revenue
1.34
Rating
None
Target Price
$2.27
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Liquidia Corporation | $37.66 | — | $3.32 B | — | -26.74% | -1.11% | $46.67 / $11.85 | $0.51 |
| 2. | SCYNEXIS, Inc. | $1.07 | — | $47.85 M | — | -30.16% | -16.48% | $1.31 / $0.56 | $1.13 |
| 3. | Aquestive Therapeutics, Inc. | $4.24 | — | $527.23 M | — | -62.98% | 178.61% | $7.55 / $2.12 | $-0.28 |
| 4. | PRF Technologies Ltd. | $2.64 | — | $2.31 M | — | -53.59% | -90.37% | $17.95 / $1.8 | $10.29 |
| 5. | TherapeuticsMD, Inc. | $2.19 | 83.93 | $25.35 M | — | -12.82% | -2.41% | $2.95 / $0.95 | $2.32 |
| 6. | Canopy Growth Corporation | $1.2 | — | $709.79 M | — | -8.06% | -48.5% | $3.28 / $1.18 | $1.49 |
| 7. | Tilray Brands, Inc. | $7.15 | — | $833.32 M | — | -6.01% | -63.16% | $23.2 / $3.51 | $14.89 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 44.53 M | 36.34 M | 33.45 M | 32.26 M | 30.3 M | — |
| Operating Profit | -6.4 M | -5.03 M | -4.56 M | -3.52 M | -11.37 M | — |
| Net Profit | -1.82 M | 25.96 M | -39.71 M | 6.12 M | 43.73 M | — |
| EPS in Rs | -0 | 0.07 | -0.1 | 0.02 | 0.12 | 0.02 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 146.59 M | 117.61 M | 87.24 M | 86.75 M |
| Operating Profit | -19.5 M | -59.55 M | -79.91 M | -104.39 M |
| Net Profit | -9.45 M | 41.08 M | -73.96 M | -168.73 M |
| EPS in Rs | -0.02 | 0.11 | -0.2 | -0.45 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.2 B | 1.17 B | 1.14 B | 1.21 B |
| Total Liabilities | 54.18 M | 55.33 M | 44.14 M | 72.05 M |
| Equity | 1.09 B | 1.06 B | 1.1 B | 1.14 B |
| Current Assets | 944.09 M | 936.11 M | 933.31 M | 960.16 M |
| Current Liabilities | 48.19 M | 49.7 M | 41.4 M | 68.12 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 25.87 M | 18.84 M | -42.84 M | -88.95 M |
| Investing CF | -76.56 M | 175.15 M | -59.5 M | -1.84 M |
| Financing CF | -19.91 M | -1.23 M | -1.03 M | -2.9 M |
| Free CF | -0.19 M | 5.69 M | -46.26 M | -93.98 M |
| Capex | -26.06 M | -13.15 M | -3.42 M | -5.03 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 34.82% | 0.57% | — | — |
| Earnings Growth % | 155.54% | 56.17% | — | — |
| Profit Margin % | 34.93% | -84.78% | -194.51% | — |
| Operating Margin % | -50.63% | -91.6% | -120.34% | — |
| Gross Margin % | 21.42% | 13.65% | 17.79% | — |
| EBITDA Margin % | -42.69% | -82.3% | -105.21% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.